Drug profile

The FDA adverse-event record for Florfenicol, Terbinafine, And Mometasone Furoate

86 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Florfenicol, Terbinafine, And Mometasone Furoate. See the species affected, top reactions, and outcomes below.

86
adverse-event reports
7.0%
death-coded share
Dog
most-reported species
21
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
86
Total Reports
6
Deaths Reported
7.0%
Death Rate

Active Ingredients

Florfenicol, Terbinafine, And Mometasone Furoate

Administration Routes

Auricular (Otic)TopicalUnknown

Species Affected

Dog 81
Cat 5

Most Affected Breeds

Retriever - Labrador 11
Terrier - Bull - American Pit 7
Crossbred Canine/dog 5
Chihuahua 4
Bulldog 3
Maltese 3
Siberian Husky 3
Pug 3
Retriever - Golden 3
Bulldog - American 3

Most Reported Reactions

Vomiting 21
Lethargy (see also Central nervous system depression in 'Neurological') 13
Diarrhoea 13
Hives (see also 'Skin') 9
Facial swelling (see also 'Skin') 8
Lack of efficacy - NOS 5
Seizure NOS 5
Anaphylaxis 5
Not eating 4
Restlessness 4
Panting 4
Fever 4

Outcome Breakdown

Ongoing
50 (58.1%)
Recovered/Normal
26 (30.2%)
Died
4 (4.7%)
Outcome Unknown
4 (4.7%)
Euthanized
2 (2.3%)

Florfenicol, Terbinafine, And Mometasone Furoate Adverse Event Insights

86 reports name Florfenicol, Terbinafine, And Mometasone Furoate; 6 recorded a death outcome (7.0% of reported events, not a population-level mortality rate). Active ingredient: Florfenicol, Terbinafine, And Mometasone Furoate. Administration routes: Auricular (Otic), Topical, Unknown.

By species: Dog (81 reports), Cat (5 reports). By breed: Retriever - Labrador (11), Terrier - Bull - American Pit (7), Crossbred Canine/dog (5).

Leading clinical signs: Vomiting (21), Lethargy (see also Central nervous system depression in 'Neurological') (13), Diarrhoea (13), Hives (see also 'Skin') (9). Outcome, 86 coded reports: Ongoing leads at 58.1%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.